Catalyst
Slingshot members are tracking this event:
OncoGenex Announces AFFINITY Phase 3 data: custirsen, in combination with cabazitaxel/prednisone failed to achieve its primary endpoint
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
OGXI |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Affinity Trial, Custirsen, Metastatic Castrate-resistant Prostate Cancer